TF and cancer: Interestingly, previous reports suggest a potential cooperativity between BCL6 and chromatin-modifying proteins such as EZH2, LSD1, and the NCOR/HDAC3 complex, suggesting that BCL6 may act as an epigenetic re-programming TF in cancers such as B-cell lymphoma.32